QIAGEN Launches “Project Q” Awareness Program
Jul 29 2010

QIAGEN Launches “Project Q” Awareness Program

QIAGEN Launches "Project Q" Awareness Program

Program aimed at demonstrating how molecular testing technologies make improvements in life possible

Shanghai, China - July 29, 2010 - QIAGEN today announced the launch of their "Project Q" awareness program in a ceremony held at Glamour Bar lounge on Shanghai's renowned Bund. The event, attended by Economic Affairs Consul Dr. Thomas Prinz of Germany, QIAGEN executives and media, showcased QIAGEN's molecular testing technologies and advanced solutions for pressing healthcare and non-healthcare related needs of China.

QIAGEN is a global leader in molecular testing technologies for advanced healthcare, research and other applications. These technologies, referred to as sample and assay technologies, are used to detect and diagnose diseases, guide treatments, drive scientific progress, and contribute to public welfare and safety as cornerstones of modern forensics, veterinary medicine, biodefense and food testing.

The "Project Q" awareness program seeks to consolidate the continuous efforts of the company, and its partners, to improve the quality of life of the Chinese people. The project is comprised of four core modules -
  - Q CSR, QIAGEN's commitment to corporate social responsibility through its long- term QIAGENcares program;
  - Dr. Q, the company's commitment to supporting academics and research, e.g. the establishment of the "QIAGEN Initiative Foundation Professorship" at the University of Science and Technology of China;
  -  Q Lab, QIAGEN's commitment to advancing research through collaboration and partnership, e.g. the "CAS/SIBS-QIAGEN Food Safety Research Collaboration"; and
  - Q Club, the company's commitment to bring together academics, industry experts, key opinion leaders and media to work towards advancing the molecular testing industry.

 "As Germany's largest biotechnology company, QIAGEN is one of the premier German multinational companies in the Chinese market", said Consul Dr. Thomas Prinz. "As a representative of the German state, I am proud to attend this event and support QIAGEN's efforts to improve the state of healthcare in China and around the world."

Examples of QIAGEN's advanced solutions include the company's food safety testing portfolio, HPV test for cervical cancer screening, and state-of-the-art disease diagnosis technology.
  - QIAGEN is continuously expanding and improving its technologies to help ensure the safety of the food supply. This year, QIAGEN expanded its food safety offerings to over 70 molecular tests, making the company's portfolio one of the largest and most diverse in the industry.
  - QIAGEN continues to work with the Chinese government to support cervical cancer screening efforts and raise awareness about the disease, of which China shares a disproportionate amount of the global burden. Every year, the company provides free HPV tests for the screening of thousands of women in over 20 provinces throughout China.
  - QIAGEN's profiling technologies detect disease with greater accuracy and higher reliability. The company is one of the leading providers of molecular tests for disease monitoring and management of Hepatitis B, which affects approximately 100 million people in China. By allowing for better management of diseases, QIAGEN technologies better address the double burden of communicable and non-communicable diseases currently burdening the Chinese healthcare system.

"QIAGEN is committed to providing state-of-the-art molecular testing solutions for the unique healthcare challenges of all of the markets we serve in Asia / China," said Dr. Victor Shi, Asia Pacific President of QIAGEN. "With strong portfolios in areas like food testing, screening, and profiling, QIAGEN is in a leadership position in addressing the diverse needs of the local market. Helping to ensure the safety of the food supply, reducing cervical cancer incidence and mortality, and helping to better diagnose disease are just a few ways in which QIAGEN products make improvements in life possible."

About QIAGEN Asia Pacific

QIAGEN Asia Pacific is the company's fastest-growing division. QIAGEN began its strategic expansion into the Asia Pacific region in 2005 and currently maintains 11 offices with over 500 employees in China, Korea, Malaysia, Singapore, India, and Australia. In 2006, QIAGEN received the Frost & Sullivan Award for Competitive Strategy Leadership in recognition of the company's strategic initiatives in the Asia Pacific molecular testing market.


QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make these isolated biomolecules visible. QIAGEN has developed and markets sample and assay products as well as automated solutions for such consumables. The Company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the first FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.

Safe Harbour Statement

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between business segments, the commercial development of the applied testing markets, personal healthcare markets, clinical research markets and proteomics markets, women's health/HPV testing markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, changing relationships with customers, suppliers and strategic partners, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate and protect its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.



Share this page